Saturday 17 October 2026
Export OPRX’s income statement to Excel — free account
OptimizeRx Corp.
OPRX Healthcare Health Information Services
OptimizeRx Corp.’s revenue for fiscal 2025 (year ended December 2025) was $109.4 million, up 18.8% from fiscal 2024. In the quarter to June 2026, revenue fell 29.8%, EPS fell 150.0%, free cash flow grew 89.9% and total debt fell 33.1%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
8.50
0.35
−3.95%
Follow OPRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 45.41 | 17.44 | 23.83 |
P/S ratio |
3.48 | 2.08 | 1.10 | 1.09 | |
P/FCF ratio |
32.93 | 12.11 | 8.12 | 5.79 | |
P/Operating CF |
118.93 | 32.09 | (252.30) | 12.48 | |
P/B ratio |
3.11 | 1.77 | 0.91 | 0.82 | |
Price to Tangible BV |
42.52 | 13.68 | 6.20 | 5.00 | |
EV/Sales |
3.56 | 2.10 | 1.13 | 1.04 | |
EV/EBITDA |
82.57 | 13.41 | 6.12 | 6.27 | |
EV/Operating CF |
32.93 | 12.28 | 8.41 | 5.55 | |
EV/FCF |
33.68 | 12.24 | 8.34 | 5.51 | |
Quick Ratio |
2.90 | 2.91 | 5.07 | 5.27 | |
Current Ratio |
3.05 | 3.04 | 5.37 | 5.58 | |
Net Debt/EBITDA |
2.60 | 0.23 | 1.75 | (4.06) | |
Debt/Assets |
16.50% | 14.51% | 13.96% | 11.57% | |
Debt/Equity |
0.23 | 0.20 | 0.18 | 0.15 | |
Asset Turnover |
0.65 | 0.63 | 0.64 | 0.59 | |
Operating CF/Net income |
4.11 | 1.41 | 0.94 | (12.25) | |
Capex/Depreciation |
(0.01) | 0.15 | (0.01) | (0.03) | |
Interest Coverage |
1.78 | 6.89 | 0.34 | (0.08) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 17.14% | 15.97% | |
Selling, General and Administrative Expense of Revenue |
55.19% | 63.46% | 50.75% | 55.78% | |
Intangible Assets out of Total Assets |
0.67 | 0.63 | 0.66 | 0.67 | |
Share Based Compensation of Revenue |
7.50% | 6.08% | 9.21% | 10.77% | |
Graham Net Nets |
0.02 | 0.07 | 0.16 | 0.19 | |
Graham Number |
0.00 | 6.48 | 7.48 | 6.14 | |
Earnings Yield |
0.00% | 2.20% | 5.73% | 4.20% | |
Free Cash Flow Yield |
3.04% | 8.26% | 12.32% | 17.28% | |
Revenue per Share |
1.40 | 1.74 | 1.06 | 1.09 | |
Operating CF per Share |
0.17 | 0.38 | (0.02) | 0.46 | |
Capex per Share |
0.00 | 0.01 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.17 | 0.39 | (0.03) | 0.46 | |
Cash per Share |
1.05 | 1.26 | 1.08 | 1.28 | |
Shareholders Equity per Share |
6.58 | 6.91 | 6.91 | 6.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.58 | 6.91 | 6.91 | 6.98 | |
Free Cash Flow |
3.19 | 7.29 | (0.49) | 8.58 | |
Working Capital |
37.85 | 43.45 | 45.71 | 44.44 | |
Capital Expenditures |
(0.01) | 0.21 | (0.02) | (0.03) | |
Net Current Asset Value |
8.26 | 16.09 | 18.51 | 20.91 | |
EV/EBIT |
57.36 | 19.65 | 8.53 | 9.39 | |
Capex to Sales |
0.00 | (0.01) | 0.00 | 0.00 | |
Price to Operating Income |
56.09 | 19.45 | 8.30 | 9.86 | |
| Other line items | |||||
Average Receivables |
30.18 | 38.36 | 32.85 | 30.64 | |
Average Payables |
2.40 | 1.90 | 3.22 | 1.65 | |
Average Assets |
167.76 | 174.04 | 167.52 | 166.79 | |
Average Common Equity |
118.36 | 122.65 | 122.94 | 125.18 |
Columns are period end dates